Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
Promis Neurosciences (PMN) is a clinical-stage biotechnology company pioneering precision antibody therapies targeting toxic misfolded proteins in neurodegenerative diseases. This page provides investors and researchers with timely updates on PMN's scientific advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of material events including regulatory milestones, research publications, and partnership announcements. Our curated news collection helps stakeholders track PMN's progress in developing treatments for Alzheimer's, ALS, and related disorders through its proprietary ProMIS™ discovery platform.
Key updates include clinical trial phase transitions, intellectual property developments, and peer-reviewed data disclosures. Bookmark this page for direct access to verified press releases and objective analysis of PMN's position in the neurodegenerative therapeutics landscape.
ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
- A favorable safety profile and tolerability across four ascending dose levels
- Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
- Potential for target engagement in Alzheimer's patients
PMN310 was well-tolerated with no serious adverse events observed. The antibody demonstrated dose proportionality in CSF and a half-life of approximately 25 days, supporting monthly dosing. ProMIS plans to advance PMN310 into a Phase 1b study in Alzheimer's patients in the second half of 2024.
ProMIS Neurosciences (Nasdaq: PMN) has announced a private placement financing of up to $122.7 million. The deal includes an upfront $30.3 million and potential additional $92.4 million from warrant exercises. The financing involves issuing Common Share Units and Pre-Funded Units at $2.15 and $2.14 per unit, respectively. Each unit includes various warrants with different exercise prices and expiration conditions.
The funds will support the development of PMN310, ProMIS' lead antibody therapeutic for Alzheimer's disease. The financing is expected to close on July 31, 2024, subject to conditions. Notable investors include Great Point Partners, Armistice Capital, and Ally Bridge Group. Guggenheim Securities led the placement, with Ceros Financial Services and Leede Financial as additional agents.
ProMIS Neurosciences (Nasdaq: PMN) reported its Q1 2024 financial results and corporate updates. The company is progressing with its Phase 1a clinical trial of PMN310 for Alzheimer's disease (AD), expecting top-line data by mid-2024. The trial evaluates safety, tolerability, and pharmacokinetics in healthy volunteers. ProMIS also plans a Phase 1b study in H2 2024. Recent publications support PMN310’s potential. In the ALS program, PMN267 showed promising preclinical data. ProMIS selected PMN400 as a lead vaccine candidate for synucleinopathies. Financially, ProMIS reported a cash decrease to $2.5M, R&D expenses of $2.1M, G&A expenses of $1.6M, and a net loss of $3.6M.
ProMIS Neurosciences Inc. published a study highlighting the selectivity of PMN310 in targeting toxic soluble aggregates in neurodegenerative diseases such as Alzheimer’s disease. The study shows PMN310's differentiation from other amyloid-beta-directed antibodies and its potential to improve efficacy and reduce risk associated with plaque-binding therapies. PMN310 is currently undergoing Phase 1a clinical studies, with promising initial data expected in mid-2024.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
